Composition of the Nomination Committee of Orion Corporation

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
26 APRIL 2024 at 11.15 EEST          

        
Composition of the Nomination Committee of Orion Corporation

The Board of Directors of Orion Corporation has appointed the following persons to the Nomination Committee of the company:

  • Annika Ekman
  • Petteri Karttunen
  • Minna Maasilta
  • Veli-Matti Mattila
  • Hilpi Rautelin
  • Seppo Salonen

Hilpi Rautelin was appointed as Chair of the Committee.  

The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board.

The essentials of the charter of the Nomination Committee and a description of the appointment process of its members are provided at https://www.orion.fi/en/investors/corporate-governance/board-of-directors/nomination-committee/charter-of-the-nomination-committee/ , a page in the Corporate Governance section of the Orion Group website.

Orion Corporation

Liisa Hurme
President and CEO
    Olli Huotari
SVP, Corporate Functions
 

                                                
Contact person:
Olli Huotari, SVP, Corporate Functions, Secretary to the Board of Directors of Orion Corporation

tel. +358 10 426 3054

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion’s net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.

 

Staff

Recent Posts

Delivra Health Brands, and Its Dream Water(R) Brand, Partners with QVC to Bring Dream Water to Online Shoppers Across the US

Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB:…

3 hours ago

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering

Philadelphia, Pennsylvania--(Newsfile Corp. - June 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company")…

6 hours ago

Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation

ARLINGTON, Va.--(BUSINESS WIRE)--The National Evaluation System for health Technology (NEST), an initiative of the Medical…

8 hours ago

“Regulatory Uncertainty is Slowing Innovation: New Survey of 486 Life Science Professionals Reveals Gaps in Compliance Readiness and Confidence”

ARLINGTON, Va., June 2, 2025 /PRNewswire/ -- BioInformatics, a Science and Medicine Group company, has released…

8 hours ago

Scripta Insights and RxSaveCard Partner to Help Self-Insured Employers Cut Prescription Drug Costs and Strengthen Fiduciary Compliance

New Collaboration Integrates Low-Cost Cash Pay Options into Scripta's Rx Navigation™ Platform, Supporting Fiduciary Responsibility…

8 hours ago

Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date

Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely…

8 hours ago